Price$82.44+3.60 (+4.57%)
01:30 PM07:45 PM
News · 26 weeks66+17%
2026-03-012026-08-23
Mix2790d
- Insider10(37%)
- Other9(33%)
- SEC Filings4(15%)
- Analyst2(7%)
- Earnings2(7%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
- PRGRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection TestMENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026 to review the Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test. The Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer before symptoms appear, including cancers that do not have recommen
- SECSEC Form SCHEDULE 13G filed by GRAIL Inc.SCHEDULE 13G - GRAIL, Inc. (0001699031) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
- SECSEC Form 10-Q filed by GRAIL Inc.10-Q - GRAIL, Inc. (0001699031) (Filer)
- SECGRAIL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GRAIL, Inc. (0001699031) (Filer)
- PRGRAIL Reports Second Quarter 2026 Financial ResultsQ2 Galleri® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the YearNHS-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri Completed $110 Million Equity Financing With Samsung MENLO PARK, Calif., Aug. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter of 2026.
- PRGRAIL to Present at the Canaccord Genuity 46th Annual Growth ConferenceMENLO PARK, Calif., July 30, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, Aug. 11 at 10:00 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL
- PRGRAIL to Announce Second Quarter 2026 Financial ResultsMENLO PARK, Calif., July 29, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2026 following the close of market on Wednesday, Aug. 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Second Quarter 2026 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at inves
- INSIDERDirector Chase William J was granted 276 shares, increasing direct ownership by 0.65% to 42,978 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERDirector Summe Gregory L was granted 427 shares, increasing direct ownership by 0.94% to 45,672 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERDirector Mizell Steven was granted 268 shares, increasing direct ownership by 0.63% to 42,830 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- PRPriority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer PlansMENLO PARK, Calif., July 16, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025 and is expanding on its partnership with GRAIL to become the first Michigan health plan to enable its employer groups to easily add the
- PRGRAIL Completes $110 Million Equity Financing With Samsung EntitiesMENLO PARK, Calif., June 25, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. Pursuant to the definitive agreement, the Samsung entities invested $110 million in GRAIL through the purchase of shares of GRAIL common stock at a price of $70.05 per share, representing a long-term investment in support of GRAIL's growth and international expansion objectives."This investment from the Samsung entities further strengthens o
- INSIDERDirector Mizell Steven was granted 5,491 shares, increasing direct ownership by 15% to 42,562 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERDirector Chase William J was granted 5,491 shares, increasing direct ownership by 15% to 42,702 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERDirector Summe Gregory L was granted 5,491 shares, increasing direct ownership by 14% to 45,245 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERDirector Krevans Sarah was granted 5,491 shares, increasing direct ownership by 15% to 42,628 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- SECGRAIL Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - GRAIL, Inc. (0001699031) (Filer)
- INSIDERChief Growth Officer Partridge Andrew John sold $91,070 worth of shares (1,491 units at $61.08), decreasing direct ownership by 0.90% to 163,738 units (SEC Form 4) (withholding obligation)4 - GRAIL, Inc. (0001699031) (Issuer)
- ANALYSTGoldman initiated coverage on GRAIL with a new price targetGoldman initiated coverage of GRAIL with a rating of Neutral and set a new price target of $60.00
- INSIDERChief Executive Officer Ofman Joshua J. was granted 31,055 shares, increasing direct ownership by 8% to 402,271 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERNew insider Partridge Andrew John claimed ownership of 165,229 shares (SEC Form 3)3 - GRAIL, Inc. (0001699031) (Issuer)
- ANALYSTWolfe Research resumed coverage on GRAILWolfe Research resumed coverage of GRAIL with a rating of Peer Perform
- SECGRAIL Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - GRAIL, Inc. (0001699031) (Filer)
GRAL FAQ
5 questionsWhere does GRAL stock trade?
GRAIL Inc. (GRAL) is listed on NASDAQ.What sector and industry is GRAL in?
GRAIL Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about GRAL?
GRAIL Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral on 2026-06-05.What companies are similar to GRAL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare GRAL side-by-side with any of them on Quantisnow.How can I track GRAL on Quantisnow?
Quantisnow aggregates GRAIL Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRAL to receive live email and push alerts on every new disclosure.